stoxline Quote Chart Rank Option Currency Glossary
  
Absci Corporation (ABSI)
4.69  0.01 (0.21%)    02-23 16:00
Open: 4.73
High: 4.85
Volume: 865,615
  
Pre. Close: 4.68
Low: 4.51
Market Cap: 436(M)
Technical analysis
2024-02-23 4:34:44 PM
Short term     
Mid term     
Targets 6-month :  6.31 1-year :  7.37
Resists First :  5.4 Second :  6.31
Pivot price 4.55
Supports First :  3.97 Second :  3.08
MAs MA(5) :  4.88 MA(20) :  4.41
MA(100) :  2.69 MA(250) :  2.1
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  59.6 D(3) :  65.9
RSI RSI(14): 56.3
52-week High :  5.46 Low :  1.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABSI ] has closed below upper band by 41.2%. Bollinger Bands are 47.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.85 - 4.88 4.88 - 4.9
Low: 4.46 - 4.48 4.48 - 4.5
Close: 4.65 - 4.69 4.69 - 4.73
Company Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Headline News

Wed, 21 Feb 2024
Absci initiates IND-enabling studies for ABS-101 - TipRanks.com - TipRanks

Wed, 21 Feb 2024
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research

Wed, 21 Feb 2024
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and ... - Marketscreener.com

Wed, 21 Feb 2024
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and ... - Marketscreener.com

Tue, 20 Feb 2024
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire

Fri, 16 Feb 2024
Premarket Mover: Absci Corp (ABSI) Up 2.33% - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 93 (M)
Held by Insiders 6.106e+007 (%)
Held by Institutions 26.1 (%)
Shares Short 2,010 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.568e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 132.1 %
Return on Equity (ttm) -19.5 %
Qtrly Rev. Growth 6.94e+006 %
Gross Profit (p.s.) -30.49
Sales Per Share -19.35
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -68 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.25
Price to Cash Flow 5
Stock Dividends
Dividend 0
Forward Dividend 6.09e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android